Pediatric Bronchitis
Conditions
Interventions
1:Xiyanping injection
2: blank control
Sponsors
West China Second Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
1 Years to 3 Years
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of pediatric bronchitis with hospital treatment needed; Males and female subjects aged between 1 and 3 years old; 2. With fever, cough, gasp and expectoration symptoms; 3. Have wheeze and/ or mid-fine rales on one's lungs; 4. White blood cell count < 12 x 10^9/L, categorized priority to leukocyte; 5. C-reactive protein=8mg/L or normal Super C- reactive protein; 6. Had experienced =48 hours course before enrollment; 7. Previous Wheezing episodes=2; 8. Written informed consent.
Exclusion criteria
Exclusion criteria: Participants with severe clinical symptoms, meet any of the following 1. SaO2=0.92; 2. Shock or disturbance of consciousness; 3. Significantly speed up breathing, rapid pulse accompany with severe respiratory distress; or(4)Repeated occurrence of apnea or slow and irregular respiration; 4. Acute infectious disease such as measles, pertussis and influenza; 5. Participants with bronchial asthma, bronchopneumonia and other respiratory diseases. Chronic lung diseases: 6. Participants with complicated pyopneumothorax, airway obstruction, toxic encephalopathy, cardiac failure or respiratory failure; 7. Participants with complicated severe underlying myocardial, liver, kidney, digestive and hematopoietic system diseases; 8. Severe malnutrition and history of immune deficiency which may seriously affect the self-limiting process of the course; 9. Participants with epilepsy and other disturbances of central nervous system; 10. Participants with congenital diseases and psychosis; 11. use of any other antiviral drugs within the 2 weeks before enrollment; 12. use of systemic hormone within the 2 weeks before enrollment; 13. Participants had a history of allergic constitution and drug allergy; Allergenic to XiYanPing injection and Andrographolide 14. Participants participated in other clinical research in the last three months 15. Any condition which would make the subject, in the opinion of the investigator or designee, not suitable for the study for any reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to total score of the clinical symptoms/signs decreased more than 70% from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| The total efficiency rate; | — |
Countries
China
Contacts
Public ContactLv Lang
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Outcome results
None listed